Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.69 |
| ▸ | MMP8 | P22894 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288556 | 1.00 | MMP9 (0.69) | MMP9MMP8HDAC8PPARGMME | |
| SCHEMBL3073641 | 0.90 | MMP9 (0.60) | MMP9MMP8MMEACECPA1 | |
| SCHEMBL1071045 | 0.90 | MMP9 (0.60) | MMP9MMP8BCHELTA4H | |
| SCHEMBL8935472 | 0.90 | MMP9 (0.60) | MMP9MMP8BCHELTA4H | |
| SCHEMBL8935277 | 0.90 | MMP9 (0.60) | MMP9MMP8BCHELTA4H | |
| SCHEMBL7403575 | 0.88 | MMP9 (0.57) | MMP9MMP8BCHELTA4H | |
| SCHEMBL8935375 | 0.88 | MMP9 (0.57) | MMP9MMP8BCHELTA4H | |
| SCHEMBL6034470 | 0.87 | PPARG (0.62) | MMP9MMP8PPARGMMEACE | |
| SCHEMBL6034466 | 0.87 | PPARG (0.62) | MMP9MMP8PPARGMMEACE | |
| SCHEMBL8413776 | 0.87 | PPARG (0.62) | MMP9MMP8PPARGMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| US-8710040-B2 | Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-29 | — | — | US | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| US-20120142777-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN ALPHA-AMINOAMIDE AND ITS ANALGESIC USE | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-06-07 | — | — | US | claimed |
| US-8084447-B2 | Synergistic pain treatment, side effect reduction; a mixture of pregabalin or tiagabine and 2-[4-(2-fluorobenzyloxy) benzylamino] propanamide | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-12-27 | — | — | US | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | NEWRON PHARMACEUTICALS SPA (IT) | 2010-10-21 | — | — | US | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
| US-20040248978-A1 | Pharmaceutical composition comprising gabapentin or an analogue thereof and an aminoamide and its analgesic use | NEWRON PHARMACEUTICALS SPA (IT) | 2004-12-09 | — | — | US | claimed |
| WO-2004062655-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARMACEUTICALS SPA (IT) | 2004-07-29 | — | — | WO | claimed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | claimed |
| EP-1423168-A2 | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN $G(A)-AMINOAMIDE AND ITS ANALGESIC USE | Newron Pharmaceuticals S.p.A. (IT) | 2004-06-02 | — | — | EP | claimed |
| EP-1045830-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARM SPA (IT) | 2003-04-23 | — | — | EP | claimed |
| WO-2003020273-A2 | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN $G(A)-AMINOAMIDE AND ITS ANALGESIC USE | NEWRON PHARMACEUTICALS SPA (IT) | 2003-03-13 | — | — | WO | claimed |
| US-6306903-B1 | ANALGESICS FOR ALLEVIATION OF CHRONIC AND NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-23 | — | — | US | claimed |
| EP-1045830-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-25 | — | — | EP | claimed |
| WO-1999035125-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | MMP9 4646/4885MMP8 4662/4885HDAC8 1746/4885 |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | MVD, TBXA2R, BDKRB2 | MMP9 1865/4885MMP8 534/4885HDAC8 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.